Supplemental Table 1. Summary of the stepwise building of the covariates model

Model	OFV	ΔOFV
Step 1		
Base	-3603.720	N/A
BW on (V_c)	-3604.591	-0.871
BW on (V_p)	-3605.275	-1.555
BW on (CL_{other}/F)	-3604.032	-0.312
CYP2A6 on (CL_{other}/F)	-3611.676	-7.956[*]
CYP2A6 on (CL_{f1}/F)	-3597.866	5.854
CYP3A5 on (CL_{other}/F)	-3603.720	0.000
CYP3A5 on (CL_{f2}/F)	-3613.979	-10.259[*]
CYP3A5 on (CL_{m2})	-3606.531	-2.811
CYP2B6 on (CL_{other}/F)	-3607.720	-4.000
CYP2B6 on (CL_{f2}/F)	-3628.965	-25.245[*]
CYP2B6 on (CL_{m2})	-3608.275	-4.555
CYP2B6 on (INH1)	-3615.040	-11.320[*]
CYP2B6 on (INH2)	-3607.841	-4.121
Step 2		
Base: CYP2B6 on (CL_{f2}/F)	-3628.965	N/A
CYP2B6 (CL_{f2}/F) + CYP2B6 on (INH1)	-3628.830	0.135
CYP2B6 + CYP3A5 on (CL_{f2}/F)	-3626.923	2.042
CYP2B6 on (CL_{f2}/F) + CYP2A6 on (CL_{other}/F)	-3628.965	0.000

**ΔOFV** is the difference in the value of the objective function
* indicates statistical significance at $p = 0.05$

Supplemental Figure Legends

Supplemental Figure 1 Predicted versus observed plasma concentrations of a) EFV, b) 7-OH EFV, c) 8-OH EFV displaying uniform distribution of observed concentrations around the line of identity.


Supplemental Figure 2 Visual predictive checks in the clopidogrel phase of (a) EFV, (b) 7-OH EFV, and (c) 8-OH EFV based on 1000 simulations per each CYP2B6 genotype group when clopidogrel 75 mg was administered for four days prior to EFV 200 mg. Dashed lines represent the 5th and 95th percentiles while the solid line is the median of simulated plasma concentrations.

Supplemental Figure 1

Supplemental Figure 2 (a):

A

Supplemental Figure 2 (b):

B

Supplemental Figure 2 (c):

C